Why DRMA Stock dropped -7.86% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, DRMA scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3 / 20 (institutional accumulation and options positioning), Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The weakest pillars are whale flow and insider conviction, while the cash engine is also scored low because the reported return on invested capital is negative and free cash flow yield is zero. For a prospective investor evaluating the stock today, the rating points to a business that is not currently generating cash returns on its capital, with limited institutional and insider signal support. The balance sheet pillar is comparatively the least weak, but a Piotroski F-Score of 1/9 indicates weak fundamental health signals overall. The rating's implication is that upside would depend on a change in these signals rather than on any current strength shown in the data.

Dermata Therapeutics Inc. (DRMA) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The profile does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three listed fiscal years, so the source data does not show a revenue-generating operation. Not available in source data for detailed product or customer descriptions.

Per the SEC financials, the company reported operating losses in each listed year, with FY 2024 the largest at $-12.5M and FY 2025 at $-7.8M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Reported cash rose from $3.2M in FY 2024 to $7.5M in FY 2025 per the SEC financials, while debt is listed as N/A for all periods. Not available in source data for further detail on balance sheet posture beyond these figures.

Per the recent news and catalysts section, the headlines reference a Tome cosmetic study with reported positive results, a clinical trial launch for a once-weekly product, and several SEC filing and market-coverage items dated within the prior 15 hours of the data timestamp. One headline describes a stock gain on a Thursday, and another describes "big gains" tied to positive topline results from a cosmetic study. The feed also includes a seasonal returns chart and an SEC filing dated Oct 21, 2026. Risk watch items include the single-source nature of the coverage, which consists of aggregated headlines whose underlying article bodies are not provided. Per the Butterfly Supply-Chain Graph, the supply chain is marked "NONE" with no butterfly links and no proprietary signals.

• What products or development candidates does the company have, and what is their clinical or commercial stage?
• How many months of operating cash runway does the reported FY 2025 cash balance of $7.5M represent at the reported FY 2025 free cash outflow of $-7.8M?
• What is the basis for the reported Debt as N/A, and what liabilities exist on the balance sheet?
• What were the details and outcomes of the reported Tome cosmetic study results, and do the source data contain the underlying filings?
• What is the share count and dilution history, given the market cap of $4.2M at a price of 0.84?